The DOI matches its Crossref record; 124 of the 129 references it cites were found in a registry or an index.
The estrogenic and antiestrogenic activities of androgens in female target tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“4-Dione also led to significant growth inhibition in ZR-75-1 cells, although the active concentrations (IC 50 , 15 nm) are in the upper range of the plasma concentrations (1-10 nm) found in women (215-218).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [215]
In the citing paper
“In ZR-75-1 cells, concentrations of DHT in the incubation medium similar to the plasma levels found in normal women (215-217) and breast cancer patients (Ref.218; 0.3-0.7 nm) are potent inhibitors of the mitogenic effect of E 2 and even inhibit growth in the absence of estrogens (208).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [215]
In the citing paper
“The data summarized above clearly support the hypothesis that at least part of the antagonism observed between the action of androgens and estrogens in breast cancer cells (208,211,215,240) may be explained by the heterologous downregulation of the ER by an AR-mediated mechanism.”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [215]
In the citing paper
“The concentration of DHT needed to exert a half-maximal suppression of ER binding activity (0.07-0.1 nm) is lower than the concentration known to induce binding and nuclear retention of the ER (215, 234).”
From Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone (2003) · cites this paper as [215]
Citations
Cites
Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens
Ziel, H. K., & Finkle, W. D. (1975) · New England Journal of Medicine · doi:10.1056/nejm197512042932303 · Cited by 1,007
Association of Exogenous Estrogen and Endometrial Carcinoma
SMITH, D. C. C., Prentice, R. L., Thompson, D. J., & HERRMANN, W. L. (1975) · New England Journal of Medicine · doi:10.1056/nejm197512042932302 · Cited by 960
Lippman, M. E., Bolan, G., & Huff, K. K. (1976) · PubMed · Cited by 808
Horwitz, K. B., & McGuire, W. L. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38062-6 · Cited by 798
Characterization and measurement of dehydroepiandrosterone sulfate in rat brain
Corpéchot, C., Robel, P., Axelson, M., Sjövall, J., & Baulieu, E. E. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.8.4704 · Cited by 656
Estrogen Receptors in Human Breast Cancer
Powles, T. J. (1976) · Journal of Clinical Pathology · doi:10.1136/jcp.29.5.467-d · Cited by 614
Handbook of Physiology. Section- 2
HAMILTON, W. F., & Cloth, P. D. (1967) · Anesthesiology · doi:10.1097/00000542-196701000-00101 · Cited by 533
Hershko, A., Mamont, P. S., Shields, R. L., & Tomkins, G. M. (1971) · Nature New Biology · doi:10.1038/newbio232206a0 · Cited by 516
A secreted glycoprotein induced by estrogen in human breast cancer cell lines
Westley, B. (1980) · Cell · doi:10.1016/0092-8674(80)90621-2 · Cited by 477
Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle
ABRAHAM, G. E. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-2-340 · Cited by 436
Research works printed but not linked: 8
- Baulieu, 1971, Rec. Prog. Horm. Res., 27, 351
- Boris, 1967, Uterotrophic activities of some androgenic steroids in the immature mouse, Eur. J. Steroids, 2, 539
- Costlow, 1976, Prolactin receptors and androgen-induced regression of 7,12 dimethylbenzanthracène-induced mammary carcinoma, Cancer Res., 36, 3324
- Grattarola, 1977, The hormonal background of breast non cancerous diseases, Senologia, 2, 19
- Jensen, 1962, Basic Guides to the mechanism of estrogen action, Rec. Prog. Horm. Res., 18, 387
- Loeser, 1939, Male hormone in the treatment of cancer of the breast, Acta univ. inr. contr. canc., 4, 375
- Minesita, 1965, An androgen dependant mouse mammary tumour, Cancer Res., 25, 1168
- Ulrich, 1939, La testostérone (hormone mâle) et son rôle possible dans le traitement de certains cancers du sein, Acta. un. int. cancer, 4, 377
Cited by
Sorted by citations
Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 –isomerase gene family
Simard, J., Ricketts, M.-L., Gingras, S., Soucy, P., Feltus, F. A., & Melner, M. H. (2005) · Endocrine Reviews · doi:10.1210/er.2002-0050 · Cited by 620
Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., & Pelletier, G. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0031 · Cited by 544
The role of estradiol in male reproductive function
Ramasamy, R., Schulster, M., & Bernie, A. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.173932 · Cited by 411
Desforges, J. F., & Braunstein, G. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280708 · Cited by 395
Platet, N., Cathiard, A. M., Gleizes, M., & Garcia, M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.02.001 · Cited by 368
Self-citation
Metadata
- Authors
- Rochefort, H., & Garcia, M.
- Affiliations
- Inserm (FR)
- ORCID
- Garcia, Marcel
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 1983-01
- Volume
- 23
- Issue
- 2
- Pages
- 193-216
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2023676722
- Cited by
- 107
- References
- 129
- Citations by year
- 2026: 2 · 2025: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 4 · 2013: 1 · 2012: 1
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Male Breast Health Studies
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Effects and risks of endocrine disrupting chemicals
- Keywords
- androgens, estrogenic activity, antiestrogenic activity, gynecomastia, male breast enlargement, breast histopathology
- MeSH terms
- Androgens, Animals, Breast Neoplasms, Cell Nucleus, Estrogen Antagonists, Estrogens, Female, Humans, Neoplasms, Receptors, Estrogen, Receptors, Progesterone, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
